EUpALS

European organization for professionals and people with ALS

[EUpALS @EUpALS]

EUpALS is partner in EU Horizon project https://t.co/tqzKMbgct2.

End 2026 we organise a Final Symposium, including a patients dedicated session.

Patients and patient organisations can help decide the theme. Scan the QR code or go to https://t.co/kYpjrfRLBI with code 5196 8269.

[EUpALS @EUpALS]

EUpALS Industry Partner @Corcept announces an update of the Phase 2 DAZALS study of Dazucorilant, demonstrating two-year overall survival benefit in patients with ALS.

Read the attached press release.

#EUpALS #Togetherwearestrong

[EUpALS @EUpALS]

EUpALS Industry Partner @Novartis announces completion of enrollment of Phase 2 ASTRALS trial with VHB937 in ALS.
Read attached Community Statement about the number of patients enrolled, how VHB937 works, and expected time when the community will hear next update from Novartis.

[EUpALS @EUpALS]

EUpALS is partner in EU project @Real4Reg, in which ALS is a use case.

Join our online Patients Workshop on 13 April 2026 (15:00-16:30 CET) entitled “Real-World Data and Patients: Breaking the Ice” by registering for free at https://t.co/vFEEfLFvSA

[EUpALS @EUpALS]

EUpALS Industry Partners @ferrerforgood and @PrileniaTx jointly announce first enrollment in the PREVAiLS Phase 3 study of pridopidine in people with rapidly progressive ALS early in their disease course.
Recruitment at additional sites including EU is expected in coming weeks.

[EUpALS @EUpALS]

The EUpALS Newsletter Spring 2026 edition is out.

Read this and previous issues at https://t.co/Ss0khFEoek
Don't miss future ones by signing up via https://t.co/cStJ9t3m5u

[EUpALS @EUpALS]

EUpALS brings to your attention the questionnaire for people with ALS and their carers, developed by the ERN-NMD.

The survey in multiple European languages can be found at https://t.co/AUv8Waxdd4

Please distribute to your pALS and cALS.

[EUpALS @EUpALS]

EUpALS Industry Partner @NeurosenseT announces publication of results from PARADIGM Phase 2b clinical trial of PrimeC in ALS in JAMA Neurology.
The article presents integrated analysis of PrimeC’s safety profile, clinical outcomes, and biomarker findings over 18 months in pALS.

[EUpALS @EUpALS]

February 11-13, EUpALS attended the TRICALS Masterclass 2026.
Researchers, industry, patient (advocates) and regulators joined forces to improve and accelerate development of ALS treatments.
Watch the aftermovie at
https://t.co/niQcZvMHwQ

#EUpALS #TRICALS #TogetherWeAreStrong

[EUpALS @EUpALS]

Today is Global Rare Disease Day!

Despite #ALS/#MND is classified as a rare/orphan disease, no less than 50.000 European people live with ALS.

Support the @rarediseaseday campaign by sharing this message.

#RareDiseaseDay #EUpALS #TogetherWeAreStrong

[EUpALS @EUpALS]

BREAKING

EUpALS Industry Partner @argenxglobal shares an update on the adimanebart Phase 2a reALISe study in people living with #ALS/#MND.

Please, read the attached community statement.

#EUpALS #TogetherWeAreStrong

[EUpALS @EUpALS]

EUpALS is partner in EU Horizon project @Hereditary_EU .

Last week we attended the Plenary Meeting 2026 in Lisbon (Portugal).

The infrastructure for federated multimodal data sharing is into place, ready to analyze the data for the #ALS/#MND use case.

#TogetherWeAreStrong

[EUpALS @EUpALS]

EUpALS Industry Partner Vectory Therapeutics announces first participant dosed in PIONEER-ALS Phase1/2 trial of VTx-002, a First-in-Class vectorized antibody targeting TDP-43 pathology in #ALS. The company expects continuing enrolling participants across multiple clinical sites

[EUpALS @EUpALS]

EUpALS wishes you a happy and prosperous 2026 !
And we have some exciting news right away.

Over the last weeks, we have been working hard behind the scenes to construct our new EUpALS website. Be the first to discover its new look and functionalities at https://t.co/5NEtfXXWAO

[EUpALS @EUpALS]

EUpALS is partner in EU project @Real4Reg, in which ALS is a use case.

Join our online Experts Workshop on 27 January 2026 (11:30-13 CET) entitled “Real4Reg Use Case 1 – Lessons Learned on Exploring Real-World Data” by registering for free at https://t.co/tmpWM6uuwh

[EUpALS @EUpALS]

EUpALS Industry Partner @biogen published long term results from the QALSODY Phase 3 VALOR study and its open-label extension in SOD1-#ALS.

Read the attached press release, and full paper at https://t.co/dnwauWl1ZA

[EUpALS @EUpALS]

The EUpALS Newsletter Winter 2025 edition is out. Read this and previous issues at https://t.co/9iSsJJ9gJx
Don't miss future ones by signing up via https://t.co/GIyGXk4uR4

[EUpALS @EUpALS]

EUpALS is partner in EU project @Hereditary_EU. By liking this forwarded video post, EU residents can win a special #XMAS giveaway of our exclusive project materials.

Pimp up your upcomming winter break and give us a like!

#EUpALS #Togetherwearestrong

[HEREDITARY @Hereditary_EU]

🧬 HEREDITARY #XMAS Giveaway! ✨

To thank you all for your support throughout the year, the HEREDITARY project is celebrating the holiday season with a special giveaway of exclusive project materials!

Good luck to all, and happy holidays! ❄️🎁

[EUpALS @EUpALS]

EUpALS Industry Partner Vectory Therapeutics received FDA clearance to proceed with PIONEER-ALS Phase1/2 trial of VTx-002, a First-in-Class vectorized antibody targeting TDP-43 pathology in #ALS.

The open label study will evaluate 2 dose levels of VTx-002 in 12 adults with ALS.

[EUpALS @EUpALS]

Fantastic news!
Upon nomination by @ALSBelgium, EUpALS Scientific Expert Board member Prof. Philip Van Damme @UZLeuven @leuvenbrainins1 #TRICALS received the @ALSMNDAlliance Forbes Norris Award 2025.
A true recognition for his excellent international #ALS/#MND research and care!